
usd pm et
summari zoeti inc global develop anim vaccin medicin diagnost sold
veterinarian livestock produc
price-to-earnings oper ep
risk assess reflect compani strong
posit global anim heath market
possess attract product divers geograph
reach risk rate also reflect strong growth
potenti see global pet ownership rate middl
class expand less develop market also less
expos research develop patent
reimburs risk face tradit human
pharmaceut firm view posit factor
somewhat mitig risk shrink market
livestock drug consum trend toward meat
may ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
stock trade
report robust perform
revenu yoy growth
led companion anim sale
revenu yoy aid
juli acquisit abaxi
maker veterinari diagnost companion
also see strong organ growth driven
intern demand healthi
consum increas pet spend
view companion growth off-set
yoy drop livestock revenu
think intern companion
excel long-term growth opportun
pet ownership rate rise median
incom think foreign market
expand middl class drive long-term
demand growth companion anim health
see prolong stagnat though rise
imit meat potenti hurt
estim adj ep rise
yoy within
guidanc rang view
includ share repurchas none
rest think keep
cash crisi despit
buy-back author remain
march cut target
base price-to-earnings
histor forward price-to-earnings averag due solid
long-term growth prospect pet health
product cut adj ep estim
expect headwind
back increas risk due
think durabl price power
pois long-term growth companion
critic custom often difficult
replac due structur barrier gener
competit anim drug view
see attract growth potenti emerg
market total sale
pet ownership rate current
main short-term risk
view expect econom slowdown
china sale result lower
activ pharma ingredi china
amplif coronaviru could disturb
suppli chain risk view includ
lower livestock demand due shift
consum tast declin pet
ownership driven weak economi
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
execut vice-president chief
corpor overview zoeti among top global competitor discoveri develop
manufactur market anim health medicin vaccin focu livestock
companion anim compani market divers rang product livestock speci cattl
beef dairi swine poultri sheep fish companion anim speci dog cat
hors chief product categori anti-infect vaccin parasiticid medic feed addit
pharmaceut product also offer diagnost devic anim health product
compani directli market product countri product sold anoth nation
non-direct channel sale account total emerg
market brazil china india mexico account brazil largest intern
market sale account total
product companion anim primarili dog cat repres sale princip
brand includ clavamox covinia terramycin anti-infect vanguard vaccin
revolution/stronghold parasiticid growth busi driven econom develop relat
increas dispos incom pet ownership companion anim live longer increas medic
treatment companion anim advanc anim health medicin vaccin emerg
market signific long-term growth opportun companion anim segment view
nation pet ownership rate countri typic least due lower
discretionari incom median incom rise fast mani especi china india
popul billion
livestock farm anim product mainli cattl swine account sale
compris item cattl swine poultri fish sheep primari livestock categori includ
antibiot vaccin parasiticid long-term macro driver livestock product includ growth
global popul rise standard live rise demand improv nutrit particularli
competit advantag primari advantag see price power anim
pharmaceut vaccin medicin critic veterinarian livestock produc
keep anim healthi custom happi mani case product replac
due rel lack gener competit anim drug compar human pharmaceut
present believ well-capit gener anim pharmaceut produc oper
global scale compet expect one emerg due uniqu barrier gener
entri anim pharmaceut busi
primari obstacl see anim gener larg invest requir drug
coupl dynam veterinarian livestock produc frequent deal directli
anim pharmaceut maker payment distribut contrast human
pharmaceut market payment shipment mostli flow nation drug distributor
pharmaci benefit manag respect absenc middlemen fragment anim health
custom base view make less attract gener compani make larg up-front
invest develop anim drug larg multi-year invest would
face uncertainti fight individu custom rather abl immedi sell
larg volum nation drug distributor human gener
arrang strateg allianc divestitur busi part overal
strategi drive global growth place great emphasi spawn extens
diversifi product portfolio line strategi compani pursu develop new
vaccin emerg infecti diseas anim spent million revenu
 rel similar level million revenu
juli complet acquisit abaxi inc california corpor focus
develop manufactur market diagnost instrument veterinari point-of-car servic
acquir outstand common share abaxi per share cash result
abaxi becom wholly-own subsidiari acquisit enhanc presenc grow
market veterinari diagnost acquisit date fair valu consider transfer
approxim billion paid primarili new debt billion well cash hand
competit landscap prior zoeti apart larg pharmaceut firm
compani still primarili compet anim health divis within larg pharmaceut firm
competitor includ merck anim health divis merial anim health divis sanofi
elanco former subsidiari public bayer anim health novarti anim health
estim largest player anim health market term revenu
financi trend sale risen billion billion repres
three-year compound annual growth rate adjust pre-tax incom per share risen
repres three-year compound-annual-growth-rate improv profit margin
primari driver growth earn per share outpac sale growth leverag
level modest view net debt/ebitda decemb
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
neutral sinc march technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
outlook sub-industri
next year neutral expect
modest revenu growth driven
recent slowdown novel drug approv
potenti new industri price regul
neg partial off-set
upcom period low patent expir
also expect major gener maker continu
struggl due lower-cost emerg
follow banner year novel drug approv
fda signific
slowdown occur think
weigh drug maker revenu growth next
year novel brand drug enter market
gener competit often rival brand
either provid signific boost
revenu firm market
total number fda novel drug
approv fell versu
expect mean less revenu boost
major brand drug maker year ahead
estim sub-industri total
 spend pace
yoy declin septemb like
reflect effort maintain margin
sluggish revenu growth year ahead
addit fewer new brand enter
risk new price rule view
accord studi wall street
govern health system develop
countri like england norway canada
often pay less major drug
medicar kaiser famili foundat
poll indic american feel
drug cost unreason believ
dynam rais pressur drug maker
curtail usual price hike
politician enact polici lower
drug cost voter accordingli sever new
propos lower drug price emerg
side isl recent month
includ bill hous democrat
would allow medicar directli negoti
price drug maker senat
maximum medicar drug plan shift
cost burden drug maker
unclear new propos
enough support becom law see
polit parti increas focu
control drug cost signific risk
weigh outlook
balanc neg factor face
brand drug maker upcom period
low patent expir typic
biggest revenu headwind loss patent
protect open door gener
biosimilar competit base data
evaluatepharma annual global drug sale
risk expir patent averag
total forecast
drop fewer
patent cliff year ahead
major posit brand drug revenu
beyond brand firm make lion
share sub-industri market cap outlook
gener drug firm neg think
india-bas gener maker continu
take market share develop nation
firm due lower product cost
saw occur last year establish firm
like israel-bas teva saw sale
declin year-to-d thru sale
india-bas aurobindo sun pharma
grew yoy think due
rise broader composit
base index
five-year market price perform
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
analyst research note compani news
et cfra keep strong buy opinion share zoeti inc
cut target base price-to-earnings
ztss histor forward price-to-earnings averag due solid
long-term growth prospect pet health product lower
adj ep estim expect slightli lower
ep back increas headwind stem shock
cut adj ep estim start
think durabl price power pois sustain
long-term growth companion anim segment revenu
yoy ztss anim health product critic custom often
difficult replac due structur barrier gener competit
anim drug see solid long-term growth potenti emerg market
total sale pet ownership rate current
 despit like slowdown first three quarter
due disrupt caus crisi /sel hardi
pm et cfra keep hold opinion share zoeti inc
lift price target ep estim --
histor forward price-to-earnings averag due rapid growth pet-rel sale
maintain ep estim start ep
vs beat consensu revenu grew yoy
companion anim total yoy lead way demand growth
pet medic think companion healthi long-term growth runway
expect global pet ownership keep rise middl class expand
emerg market livestock sale total fell yoy howev
think segment long-term growth could limit rapid uptak
plant-bas meat imit adjust ep grew yoy see pace
come slightli without benefit last year abaxi
acquisit keep hold rate current valuat alreadi reflect
strong market posit growth prospect view /colin scarola
et cfra keep hold opinion share zoeti inc
lift target ep estim
histor forward price-to-earnings averag due rapid growth pet-rel sale
rais ep estim
ep vs beat consensu sale rose yoy
led companion anim total sale grew yoy aid
abaxi acquisit juli livestock sale continu
declin howev sale drop yoy drop yoy
cattl swine product poultri fish saw sale rise strong demand
though reflect long-term trend toward healthier eat view
adjust pre-tax incom per share grew yoy slightli slower
revenu jump sg restructur expens compress margin yoy
expect margin improv cost synergi abaxi
realiz see alreadi reflect valuat think
near fair valu /colin scarola
et cfra rais opinion share zoeti inc strong buy
buy rais target base
price-to-earnings ztss histor forward price-to-earnings averag due rapid
long-term growth see pet health product maintain
adj ep estim adj ep estim
adjust ep vs came consensu
report robust perform revenu yoy thank
strong growth market total particularli
total saw healthi yoy growth thank strong growth companion
anim offset declin livestock view
livestock total long-term growth could limit rapid
uptak plant-bas meat imit howev encourag
companion anim fast growth yoy expect global pet
ownership keep rise middl class expand emerg market /sel
pm et cfra keep buy opinion share zoeti inc
lift target ep estim --
histor forward price-to-earnings averag due rapid long-term growth expect
pet health busi especi emerg market increas
ep estim
analysi show pet ownership close tie incom level
view strong posit capit rise anim health demand
 revenu rise wage put pet ownership
within reach worker also larg emerg market
revenu like china india brazil market like china india
billion peopl pet ownership rate current
estim lead us forecast hold tremend long-term
growth opportun opportun combin
durabl price power warrant premium valuat histor averag
view /colin scarola
pm et cfra lift opinion share zoeti inc buy hold
lift target ep estim --
histor forward price-to-earnings averag due rapid long-term growth
see pet health product gener revenu
anim health market think durabl price power view
base difficult replac natur mani anim pharmaceut
believ significantli less gener competit anim drug vs
human also see low polit risk anim drug vs human outsid
 estim revenu gener emerg market
tremend growth potenti market like china india billion
peopl pet ownership rate current
two countri also grow per capita roughli annual dwarf
develop economi pet ownership highli correl
incom view see attract trajectori pet spend
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd fiscal year analyst estim
earn per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
